CYP2D6 Phenotype as a Predictor of Adverse Drug Reactions in Patients Treated With Trazodone
Our findings suggest that mCPP could contribute to trazodone-related ADRs, especially in individuals with reduced CYP2D6 metabolism. Larger clinical studies are needed to confirm that CYP2D6 genotyping could contribute to preventing ADRs in clinical practice.
Authors
- Florine M. Wiss (ORCID: https://orcid.org/0009-0001-3618-4679)
- Christian Krieg
- Samuel Allemann (ORCID: https://orcid.org/0000-0003-4067-9401)
- Céline K. Stäuble (ORCID: https://orcid.org/0000-0002-2437-4803)
- Thorsten Mikoteit (ORCID: https://orcid.org/0000-0003-2166-6330)
- C. A. Imboden
- Markus L. Lampert
- Henriette E. Meyer zu Schwabedissen
Institutions
- University of Bern (CH)
- University of Basel (CH)
- University Hospital of Bern (CH)
- Solothurner Spitäler (CH)
- Department of Biomedicine Basel (CH)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1097/jcp.0000000000002123
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00